January 2020
Prostate Cancer Clinical Trial Update With Dr. Keith Crawford (PHEN)
Prostate Cancer Clinical Trial Update With Dr. Keith Crawford. Visit Prostate Health Education Network for more information on prostate cancer and clinical trials.
Prostate Cancer Clinical Trials Update With Dr. Keith Crawford (PHEN)
December 2019 Clinical Trials Update With Dr. Keith Crawford from the Prostate Health Education Network Visit http://www.prostatehealthed.org/phen_tv_video.php?tv_id=291 for monthly updates on clinical trials
African American Prostate Cancer Healthcare Disparity - Biology or Access? (PHEN Summit 2019)
The 2019 PHEN Summit was moderated by Dr. James Roberson and speakers included Brandon Mahal, MD and Daniel George, MD discussing the African American prostate cancer health disparity. Visit http://prostatehealthed.org/ for more from PHEN on prostate cancer and clinical trials.
Minorities More Likely To Participate In Clinical Trials If Recommended by A Minority Clinician
According to the National Institute of Health (NIH), fewer than 10% of patients enrolled in clinical trials are minorities. This begs the question whether clinical trials data and research are truly relevant. Dr. Consuelo Hopkins Wilkins is a researcher at Washington University School of Medicine in St. Louis who experiences challenges recruiting older African Americans...
Long-Term Analysis of MINDACT Trial Data Finds Age-Based Disparities Based on Genetic Risk Category
The MINDACT trial sought to create a systematic comparison of therapeutic outcomes for different populations stratified according to clinical and genomic risk categories. Of the 6693 patients involved, all were categorized as a combination of clinical-high, clinical-low, genomic-high and genomic-low risk. The intended outcome of the trial was to determine if clinical-low, genomic-high patients, and...
Astellas & Pfizer's Enzalutamide Receives FDA-Approval for Treatment of Metastatic Castration-Sensitive Prostate Cancer
On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). FDA previously approved enzalutamide for patients with castration-resistant prostate cancer. Efficacy was investigated in ARCHES (NCT02677896), a trial enrolling 1150 patients with mCSPC randomized (1:1) to receive either enzalutamide orally 160 mg once...
Study Suggests BMI Affects Multiple Sclerosis Disease Progression
A recent study suggests that there may be a link between MS progression and blood lipids in MS patients who are overweight or obese. The study published in the Lancet journal EBioMedicine supports previous research that hints food, diet, and exercise can help affect disease progression in MS patients. The study was conducted by researchers at the...